<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205566</url>
  </required_header>
  <id_info>
    <org_study_id>202316</org_study_id>
    <nct_id>NCT03205566</nct_id>
  </id_info>
  <brief_title>Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection</brief_title>
  <acronym>R-PrEP</acronym>
  <official_title>The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether a 7-day course of Raltegravir 400mg bd or Raltegravir&#xD;
      400mg/lamivudine 150mg bd can prevent HIV from infecting genital tissue and will relate the&#xD;
      level of drug in the blood to the level of drug in genital tissue and to the ability to of&#xD;
      HIV to infect genital tissue. As well as determining whether these regimes can provide ex&#xD;
      vivo protection against HIV, this study will also determine speed to provision of protection&#xD;
      and a 48 hour PK/PD decay profile of Raltegravir following drug cessation after attaining&#xD;
      steady state concentrations. The results will also inform all future HIV pre-exposure&#xD;
      prophylaxis studies of Raltegravir and form the basis for large scale clinical trials without&#xD;
      the need for tissue sampling. To date, efficacy studies assessing PrEP regimens have utilized&#xD;
      HIV-acquisition endpoints with the consequence being such studies are required to be large in&#xD;
      subject number in order to power observations. In addition the study will provide for the&#xD;
      first time data on HIV protection rather than just Raltegravir drug levels in tissue, and&#xD;
      allow assessment of the possibility of Raltegravir being used as an intermittent dosing&#xD;
      regimen in PrEP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-site, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD)&#xD;
      trial whereby 36 individuals (18 women and 18 men) will be randomised according to gender&#xD;
      1:1:1:1:1:1 to one of 6 arms (A 1 A 2 A 3 B 1 B 2 B 3). The result being 3 women and 3 men&#xD;
      will be in each arm. The letter dictates the ART regimen order and the number dictates the&#xD;
      time points that tissue sampling will occur on and off ART. Two ART regimes will be&#xD;
      investigated and all individuals will receive both regimes separated by a one month wash out.&#xD;
&#xD;
      Arm A (A 1 A 2 A 3): will start with 7 days Raltegravir 400mg bd and then have a one month&#xD;
      wash out before then starting 7 days Raltegravir 400mg /lamivudine 150mg bd.&#xD;
&#xD;
      Arm B (B 1 B 2 B 3): will start with 7 days Raltegravir 400mg /lamivudine 150mg bd and then&#xD;
      have a one month wash out before then starting 7 days Raltegravir 400mg bd. This will remove&#xD;
      sequential selection bias. All individuals will receive tissue sampling at baseline for ex&#xD;
      vivo analysis to ensure biopsies are infectable on challenge assays. Sampling from women will&#xD;
      avoid menstruation and if possible focus on the luteal phase of the menstrual cycle.&#xD;
      Individuals will receive another set of tissue sampling during and after ART in phase 1, have&#xD;
      a 4 week wash out period and then have another set of sampling during and after ART in phase&#xD;
      2. Individuals will therefore have 5 sets of sampling during the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2017</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV</measure>
    <time_frame>Through Study completion, an average of 55 days</time_frame>
    <description>The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina and rectum for 100% ex vivo protection from HIV .&#xD;
High viral dose challenge: ex vivo challenge of tissue with 104 TCID50/mL HIV-1BaL Low viral dose challenge: ex vivo challenge of tissue with 102 TCID50/mL HIV-1BaL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Time From First Dose of Drug to Maximum Mucosal ex Vivo Protection From HIV.</measure>
    <time_frame>Up to 7 days from first dose</time_frame>
    <description>Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Based on PE, Blood Test and Event Reporting on Raltegravir Based PrEP, in HIV Negative Individuals</measure>
    <time_frame>Through Study completion, an average of 55 days</time_frame>
    <description>Subject safety and tolerability will be determined by physical examination, blood tests and adverse event reporting. FBC, U&amp;E and LFTs will be carried out at baseline and thereafter as symptom directed. Adverse event review. If significant adverse events have been reported, these will be clinically followed in accordance to the instruction of the study physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Cessation of Mucosal ex Vivo Protection From HIV After Stopping ART at Steady State.</measure>
    <time_frame>5 days post last dose</time_frame>
    <description>Time in days from stopping antiretroviral (Raltegravir 400mg +/-lamivudine) until ex vivo protection (against high or low viral titre of HIV-1BaL) was no longer observed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>Arm A Raltegravir, then Raltegravir/Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days Raltegravir 400mg bd followed by minimum 4 weeks wash out and then 7 days Raltegravir 400mg/lamivudine 150mg (oral tablets) bd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Raltegravir/Lamivudine, then Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days followed by a minimum of 4 weeks wash out and then 7 days Raltegravir 400mg bd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir 400Mg Tab</intervention_name>
    <description>bd for 7 days</description>
    <arm_group_label>Arm A Raltegravir, then Raltegravir/Lamivudine</arm_group_label>
    <arm_group_label>Arm B Raltegravir/Lamivudine, then Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine 150Mg Tablet</intervention_name>
    <description>+ Raltegravir 400Mg tablet bd for 7 days</description>
    <arm_group_label>Arm A Raltegravir, then Raltegravir/Lamivudine</arm_group_label>
    <arm_group_label>Arm B Raltegravir/Lamivudine, then Raltegravir</arm_group_label>
    <other_name>Epivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The ability to understand and sign a written informed consent form prior to&#xD;
             participation in any screening procedures and must be willing to comply with all trial&#xD;
             requirements.&#xD;
&#xD;
          2. Male or non-pregnant, non-lactating females&#xD;
&#xD;
          3. Age between 18 to 60 years, inclusive.&#xD;
&#xD;
          4. Body Mass Index (BMI) of 16 to 35 kg/m2, inclusive.&#xD;
&#xD;
          5. Negative antibody/antigen combined test for HIV.&#xD;
&#xD;
          6. Absence of any significant health problems (in the opinion of the investigator) on the&#xD;
             basis of the screening procedures; including medical history, physical examination,&#xD;
             vital signs.&#xD;
&#xD;
          7. Women participating in sexual intercourse that could result in pregnancy -must use an&#xD;
             adequate form of contraception throughout the study and for two weeks after the study.&#xD;
             This includes intrauterine device, condoms, anatomical sterility in self or partner.&#xD;
             Oral hormonal methods and implant contraceptives are allowed but only in combination&#xD;
             with the additional protection of a barrier method.&#xD;
&#xD;
          8. Female participants may not use any vaginal products or objects or have vaginal sex&#xD;
             for 48 hours before and after the collection of vaginal fluid and vaginal biopsies.&#xD;
             This list includes tampons, female condoms, cotton wool, rags, diaphragms, cervical&#xD;
             caps (or any other vaginal barrier method),douches, lubricants, vibrators/dildos, and&#xD;
             drying agents.&#xD;
&#xD;
          9. Males participating in sexual intercourse that could result in pregnancy must use&#xD;
             condoms during the duration of the study.&#xD;
&#xD;
         10. Men and women cannot use anal products or objects including but not exclusive to&#xD;
             douches, lubricants and vibrators/dildos, butt plugs or urethral sounds or have&#xD;
             receptive anal intercourse for 48 hours before and after the collection of rectal&#xD;
             biopsies.&#xD;
&#xD;
         11. Willing to abstain from multivitamins and antacids for the study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant acute or chronic medical illness.&#xD;
&#xD;
          2. Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs or clinical laboratory determinations.&#xD;
&#xD;
          3. Positive blood screen for syphilis, hepatitis B (HBs Ag) and/or C antibodies.&#xD;
&#xD;
          4. Positive blood screen for HIV antibodies.&#xD;
&#xD;
          5. Positive screen for sexually transmitted infections at screening visit&#xD;
&#xD;
          6. High-risk behaviour for HIV infection which is defined as having one of the following&#xD;
             within three months before trial day 0 (first dose): had unprotected vaginal or anal&#xD;
             sex with a known HIV infected person or a casual partner. engaged in sex work for&#xD;
             money or drugs. acquired a bacterial sexually transmitted disease in the past 3&#xD;
             months. having a known HIV positive partner either currently or in the previous six&#xD;
             months Females who are pregnant or breast-feeding.&#xD;
&#xD;
          7. Clinically significant laboratory abnormalities (according to normal range as defined&#xD;
             by central laboratory).&#xD;
&#xD;
          8. Participation in a clinical trial of an Investigational product within 1 month of&#xD;
             planned baseline enrolment in this study.&#xD;
&#xD;
          9. Ingestion of H2 receptor antagonists or proton pump inhibitor drugs in the preceding&#xD;
             14 days&#xD;
&#xD;
         10. Current of planned use of anti-epileptics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Fox</last_name>
    <role>Study Director</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harrison Wing, Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.</citation>
    <PMID>21091279</PMID>
  </reference>
  <reference>
    <citation>García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.</citation>
    <PMID>18254653</PMID>
  </reference>
  <reference>
    <citation>Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS. 2011 Oct 23;25(16):1971-9. doi: 10.1097/QAD.0b013e32834b3629.</citation>
    <PMID>21811139</PMID>
  </reference>
  <reference>
    <citation>Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011;6(9):e23243. doi: 10.1371/journal.pone.0023243. Epub 2011 Sep 28.</citation>
    <PMID>21969851</PMID>
  </reference>
  <reference>
    <citation>O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer. 2006 Mar 13;94(5):609-13. Review.</citation>
    <PMID>16434987</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>July 21, 2020</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03205566/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential participants were identified via study poster, internal recruitment emails, and via a list of individuals who had consented to be contacted for further research. Potential participants would contact the team, trial discussed &amp; information sheet provided. If still interested, would be consented and screening visit booked.</recruitment_details>
      <pre_assignment_details>Once participants were consented to the study, they undertook a screening visits to confirm eligibility. If eligibility was not confirmed, the participant was deemed a screen failure and not randomised to the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir, Then Raltegravir/Lamivudine</title>
          <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Washout minimum of 28 days&#xD;
Raltegravir 400mg plus lamivudine 150mg taken twice a day for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Raltegravir Lamivudine, Then Raltegravir</title>
          <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Washout minimum 28 days&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">One participant withdrawn and replaced. Data obtained from first participant still used in analysis</participants>
                <participants group_id="P2" count="19">One participant withdrawn and replaced. Data obtained from first participant still used in analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir, Then Raltegravir Plus Lamivudine</title>
          <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Washout period 28 days&#xD;
Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.</description>
        </group>
        <group group_id="B2">
          <title>Raltegravir Lamivudine, Then Raltegravir</title>
          <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Washout period 28 days&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="6.5"/>
                    <measurement group_id="B2" value="30.9" spread="8.0"/>
                    <measurement group_id="B3" value="29" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV</title>
        <description>The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina and rectum for 100% ex vivo protection from HIV .&#xD;
High viral dose challenge: ex vivo challenge of tissue with 104 TCID50/mL HIV-1BaL Low viral dose challenge: ex vivo challenge of tissue with 102 TCID50/mL HIV-1BaL</description>
        <time_frame>Through Study completion, an average of 55 days</time_frame>
        <population>Excludes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir During Combination Treatment</title>
            <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days&#xD;
Lamivudine 150Mg Tablet: + Raltegravir 400Mg tablet bd for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Lamivudine During Combination Treatment</title>
            <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days&#xD;
Lamivudine 150Mg Tablet: + Raltegravir 400Mg tablet bd for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV</title>
          <description>The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina and rectum for 100% ex vivo protection from HIV .&#xD;
High viral dose challenge: ex vivo challenge of tissue with 104 TCID50/mL HIV-1BaL Low viral dose challenge: ex vivo challenge of tissue with 102 TCID50/mL HIV-1BaL</description>
          <population>Excludes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma: High Dose Challenge in rectal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples were below detection level for primary outcome</measurement>
                    <measurement group_id="O2" value="669.90" spread="231.40"/>
                    <measurement group_id="O3" value="265.10" spread="76.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma: Low viral dose challenge in rectal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="979.8" spread="306.5"/>
                    <measurement group_id="O2" value="669.90" spread="231.40"/>
                    <measurement group_id="O3" value="265.10" spread="76.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal: high viral dose challenge in rectal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples were below detection level for primary outcome</measurement>
                    <measurement group_id="O2" value="862.35" spread="237.60"/>
                    <measurement group_id="O3" value="1722.02" spread="235.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal: Low viral dose challenge in rectal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729.36" spread="218.10"/>
                    <measurement group_id="O2" value="862.35" spread="237.60"/>
                    <measurement group_id="O3" value="1722.02" spread="235.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma: high viral dose challenge in vaginal tissu</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples were below detection level for primary outcome</measurement>
                    <measurement group_id="O2" value="828.60" spread="510.30"/>
                    <measurement group_id="O3" value="266.40" spread="101.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma: low viral dose challenge in vaginal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="979.8" spread="306.5"/>
                    <measurement group_id="O2" value="281.60" spread="99.10"/>
                    <measurement group_id="O3" value="169.10" spread="19.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma: high dose in vaginal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples were below detection level for primary outcome</measurement>
                    <measurement group_id="O2" value="648.24" spread="432.90"/>
                    <measurement group_id="O3" value="1557.80" spread="206.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma: low dose in vaginal tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="607.60" spread="157.28"/>
                    <measurement group_id="O2" value="273.02" spread="88.40"/>
                    <measurement group_id="O3" value="1437.80" spread="133.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time From First Dose of Drug to Maximum Mucosal ex Vivo Protection From HIV.</title>
        <description>Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed.</description>
        <time_frame>Up to 7 days from first dose</time_frame>
        <population>Excludes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Lamivudine</title>
            <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days&#xD;
Lamivudine 150Mg Tablet: + Raltegravir 400Mg tablet bd for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Time From First Dose of Drug to Maximum Mucosal ex Vivo Protection From HIV.</title>
          <description>Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed.</description>
          <population>Excludes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time from first dose of drug to maximum rectal ex vivo protection from high titer HIV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.58"/>
                    <measurement group_id="O2" value="2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time from first dose of drug to maximum rectal ex vivo protection from low titer HIV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0"/>
                    <measurement group_id="O2" value="2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time from first dose of drug to maximum rectal ex vivo protection from High titer HIV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.67"/>
                    <measurement group_id="O2" value="3" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.45"/>
                    <measurement group_id="O2" value="3.67" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Based on PE, Blood Test and Event Reporting on Raltegravir Based PrEP, in HIV Negative Individuals</title>
        <description>Subject safety and tolerability will be determined by physical examination, blood tests and adverse event reporting. FBC, U&amp;E and LFTs will be carried out at baseline and thereafter as symptom directed. Adverse event review. If significant adverse events have been reported, these will be clinically followed in accordance to the instruction of the study physician.</description>
        <time_frame>Through Study completion, an average of 55 days</time_frame>
        <population>Includes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A Raltegravir</title>
            <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B Raltegravir Lamivudine</title>
            <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days&#xD;
Lamivudine 150Mg Tablet: + Raltegravir 400Mg tablet bd for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Based on PE, Blood Test and Event Reporting on Raltegravir Based PrEP, in HIV Negative Individuals</title>
          <description>Subject safety and tolerability will be determined by physical examination, blood tests and adverse event reporting. FBC, U&amp;E and LFTs will be carried out at baseline and thereafter as symptom directed. Adverse event review. If significant adverse events have been reported, these will be clinically followed in accordance to the instruction of the study physician.</description>
          <population>Includes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
          <units>Adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Cessation of Mucosal ex Vivo Protection From HIV After Stopping ART at Steady State.</title>
        <description>Time in days from stopping antiretroviral (Raltegravir 400mg +/-lamivudine) until ex vivo protection (against high or low viral titre of HIV-1BaL) was no longer observed.</description>
        <time_frame>5 days post last dose</time_frame>
        <population>Excludes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Lamivudine</title>
            <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days&#xD;
Lamivudine 150Mg Tablet: + Raltegravir 400Mg tablet bd for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Cessation of Mucosal ex Vivo Protection From HIV After Stopping ART at Steady State.</title>
          <description>Time in days from stopping antiretroviral (Raltegravir 400mg +/-lamivudine) until ex vivo protection (against high or low viral titre of HIV-1BaL) was no longer observed.</description>
          <population>Excludes two participants who were withdrawn from the study due to not meeting study inclusion criteria, but who were nonetheless included in safety analyses as they received at least one dose of study medication</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to cessation of rectal ex vivo protection from high HIV dose challenge post ART at steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="0.69"/>
                    <measurement group_id="O2" value="NA" spread="NA">Cessation of mucosal ex vivo protection from HIV was not reached by the end of the follow up period (5 days), therefore mean and standard error could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to cessation of rectal ex vivo protection from low HIV dose challenge post ART at steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Cessation of mucosal ex vivo protection from HIV was not reached by the end of the follow up period (5 days), therefore mean and standard error could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Cessation of mucosal ex vivo protection from HIV was not reached by the end of the follow up period (5 days), therefore mean and standard error could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to cessation of vaginal ex vivo protection from high HIVdose challenge post ART at steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.13"/>
                    <measurement group_id="O2" value="NA" spread="NA">Cessation of mucosal ex vivo protection from HIV was not reached by the end of the follow up period (5 days), therefore mean and standard error could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to cessation of vaginal ex vivo protection from low HIV dose challenge post ART at steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.26"/>
                    <measurement group_id="O2" value="NA" spread="NA">Cessation of mucosal ex vivo protection from HIV was not reached by the end of the follow up period (5 days), therefore mean and standard error could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the duration each subject participated in the trial, this being from enrollment to final visit, which is approximately 55 days.</time_frame>
      <desc>All adverse event data that was captured as part of trial participation, including that of individuals withdrawn from the trial, were used in analysis</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A Raltegravir</title>
          <description>Raltegravir 400mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Arm B Raltegravir Lamivudine</title>
          <description>Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.&#xD;
Raltegravir 400Mg Tab: bd for 7 days&#xD;
Lamivudine 150Mg Tablet: + Raltegravir 400Mg tablet bd for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal LFTs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neck lump right side</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Swollen neck glands</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acid Reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Impacted tooth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rectal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral illness with abdominal pain, vomiting, nausea, fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fluoxetine Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Rectal Discomfort and PR bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Painful left toe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Perianal lump</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Light headedness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nightmares and vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Runny nose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nose bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Spotting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Julie Fox</name_or_title>
      <organization>Guy's &amp; St. Thomas' NHS Foundation Trust</organization>
      <phone>020 7188 7188</phone>
      <email>julie.fox@gstt.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

